All News

Lung transplant recipients were found to be at heightened risk of developing secondary lung infections, including bacterial and fungal infections, due to unique risk factors.

Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.

The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.

Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.

A low-fat vegan diet reduces dietary acid load and promotes weight loss more effectively than a Mediterranean diet.

Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis.

Simplifying complex information through illustrations has consistently helped patients feel that managing type 1 diabetes is achievable.

The data revealed that only 75% of patients receive HER2-targeting therapies.

Gianni Scappaticci, PharmD, BCOP, outlines a personalized, evidence-based approach to managing steroid-refractory chronic graft-versus-host disease (cGVHD) in a post–haploidentical transplant patient, highlighting the rationale for using ruxolitinib, belumosudil, or their combination based on disease progression and fibrotic features.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

A direct link between memories and physical changes has not yet been established.

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.

Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for routine screening.

Ropeginterferon alfa-2b shows promising results in treating preprimary myelofibrosis, enhancing clinical responses and safety in patients.

Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.

Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.

Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.

A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.

Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-vs-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.

The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach for patients with the rare condition.

INCB057643 shows promise in treating myelofibrosis, enhancing anemia and symptom relief.

OTC saliva substitutes and avoiding alcohol can help alleviate dry mouth symptoms.